Further analysis of English literature on B-cell lymphomas has revealed several recent research studies utilizing cutting-edge applications of known and newly developed immunohistochemistry (IHC) markers like cyclin-D3, p63, GATA3, J-chain, cortactin, MAL-RNA encoded in situ hybridization (ISH), interferon regulatory factor 8 (IRF8), and myocyte enhancer factor 2B (MEF2B). This evidence concerns the gene CTTN and B-cell non-Hodgkin lymphoma.